Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Secures Rights to Buy Promedior

09/04/2015 | 02:40am US/Eastern

Bristol-Myers Squibb Company and Promedior have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain worldwide rights to its lead asset PRM- 151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF).

According to a release, PRM-151 has been granted Fast Track designation in the U.S. and Orphan designation in the U.S. and Europe for the treatment of MF and Orphan Designation in the U.S. and Europe for the treatment of IPF. Promedior is a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat fibrotic diseases. Total aggregate payments to Promedior under the agreement have the potential to reach $1.25 billion, which includes an upfront cash payment for the right to acquire Promedior, an exercise fee payable if Bristol-Myers Squibb elects to exercise its right to acquire the company, and subsequent clinical and regulatory milestone payments.

"Bristol-Myers Squibb continues to invest in building a diverse specialty portfolio, focusing on innovative approaches that can transform the treatment landscape for patients with serious diseases," said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. "PRM- 151 will complement our growing early-stage fibrosis portfolio, and we are excited by its potential to address multiple fibrotic diseases."

"We are pleased that Bristol-Myers Squibb has recognized the value of Promedior's clinically validated approach to directly address the underlying pathology of diseases involving fibrosis," said Suzanne L. Bruhn, Ph.D., President and Chief Executive Officer of Promedior. "With the strong strategic fit between our companies, we intend to continue to move PRM-151 forward rapidly as a new treatment option to address the unmet needs of patients with myelofibrosis, idiopathic pulmonary fibrosis, and other fibrotic diseases."

PRM-151 has been shown in multiple preclinical models to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis, including IPF, acute and chronic nephropathy, liver fibrosis, and age-related macular degeneration. Promedior has advanced PRM-151 into clinical trials focused on two orphan fibrotic diseases (MF and IPF).

Bristol-Myers Squibb is developing an early stage fibrosis portfolio that includes BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist in Phase 2 development for the treatment of idiopathic pulmonary fibrosis.

Under the terms of the agreement, Bristol-Myers Squibb noted, it will make payments aggregating up to $1.25 billion that includes an upfront cash payment of $150 million as consideration for both the right to acquire Promedior and as payment for services in support of the MF and IPF Phase 2 clinical trials. The companies have agreed on a development plan that will be executed by Promedior. It is anticipated that the Phase 2 trials in MF and IPF will be initiated in the coming weeks. Bristol-Myers Squibb can exercise its right to acquire Promedior upon completion of either of these trials.

Fibrotic diseases are characterized by the formation of excess fibrous connective tissue in an organ or tissue, compromising function and ultimately leading to organ failure. Idiopathic pulmonary fibrosis is a chronic, progressive form of lung disease characterized by the scarring of lung tissue for which there are limited treatment options. While estimates vary, it is believed that IPF could affect approximately 130,000 patients in the U.S. and approximately 76,000 patients in Europe. Myelofibrosis is a serious, life-limiting blood cancer, characterized by fibrosis of the bone marrow which prevents the normal production of blood cells, leading to anemia, fatigue, and increased risk of bleeding and infection.

Promedior is a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.

Bristol-Myers Squibb is a global biopharmaceutical company.

More information:

www.bms.com

www.promedior.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
02:40a BRISTOL MYERS SQUIBB : Secures Rights to Buy Promedior
09/03 BRISTOL MYERS SQUIBB : U.S. FDA Accepts for Priority Review the Biologics Licens..
09/02 BRISTOL MYERS SQUIBB : An Application for the Trademark "ENFLORA" Has Been Filed..
09/02 Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical ..
09/02 BRISTOL MYERS SQUIBB : Data from Bristol-Myers Squibb Provide New Insights into ..
09/02 BRISTOL MYERS SQUIBB : Trademark Application for "AIM: ABATACEPT IN INADEQUATE R..
09/02 BRISTOL MYERS SQUIBB : to Present New Data from its Immuno-Oncology Clinical Dev..
09/02 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Reveals New Findings o..
09/02 BRISTOL MYERS SQUIBB : Study Results from Bristol-Myers Squibb Broaden Understan..
09/02 BRISTOL MYERS SQUIBB : to Host Investor Teleconference to Discuss World Conferen..
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials